###### Practice points

-   Despite progress in the treatment of advanced melanoma, 5-year survival rates remain moderately low.

-   Advanced melanoma with activating *BRAF* mutations have been associated with an increased risk of death due to rapid disease progression.

-   Limited data are available regarding treatment patterns for patients with activating *BRAF* mutations, and changing treatment options necessitates updating published analyses of US electronic medical records.

-   Our results indicate that treatment patterns for advanced melanoma dramatically changed from 2011 to 2017.

-   Checkpoint inhibitors were the most commonly prescribed drug therapy overall for patients with advanced melanoma, regardless of *BRAF* mutation and stage, and BRAF/MEK inhibitors were the second most common.

-   Other targeted therapies were rarely used, and cytokine and chemotherapy usage declined from 2011 to 2017.

-   BRAF inhibitor monotherapies are being replaced by BRAF/MEK combination inhibitors.

-   As new agents are approved for melanoma, ongoing surveillance of treatment patterns will be necessary to capture the changing landscape of treatment options.

Melanoma, the fifth most common cancer diagnosis in the USA accounted for 5.3% of all new cancer diagnoses and 1.5% of all cancer deaths in 2018 \[[@B1]\]. Advanced melanoma, a rare and serious type of skin cancer, is responsible for most skin cancer--related deaths \[[@B2]\], despite representing only 1% of skin cancer cases \[[@B2]\]. Although there has been progress in the treatment of advanced melanoma \[[@B3]\], 5-year survival rates remain moderately low at approximately 60% for patients presenting with stage III melanoma and 20% for those with stage IV disease \[[@B1]\]. In addition, cases of advanced melanoma that involve activating *BRAF* mutations have been associated with up to a threefold increased risk of death over a 7.6-year follow-up period due to more rapidly progressing disease, compared with melanoma without *BRAF* mutations \[[@B4],[@B5]\].

Since 2011, the previously low survival rates of advanced melanoma have improved as a result of approvals of new immunotherapies, including ipilimumab (2011) \[[@B6]\], pembrolizumab (2014) \[[@B7]\] and nivolumab (2014) \[[@B8]\] that have dramatically changed the treatment landscape, response rates and other outcomes in advanced melanoma \[[@B9]\]. Talimogene laherparepvec, an intralesional oncolytic immunotherapy, was approved in 2015 \[[@B10]\] and may lead to further changes in treatment patterns in the future. In addition to the development of new BRAF/MEK inhibitors to treat *BRAF* mutant (*BRAF^Mut^*) melanomas (vemurafenib \[2011\] \[[@B11]\], dabrafenib \[2013\] \[[@B12]\], encorafenib \[2018\] \[[@B13]\], trametinib \[2013\] \[[@B14]\], cobimetinib \[2015\] \[[@B15]\] and binimetinib \[2018\] \[[@B16]\]), there is ongoing investigation of therapeutic combinations, including triplet therapy in the management of this melanoma subtype \[[@B9]\].

Limited data are available regarding treatment patterns for patients with *BRAF^Mut^* melanoma, and the rapidly changing set of treatment options warrants updating published analyses of US electronic medical records (EMRs) \[[@B17]\]. We are aware of only two other studies reporting EMR analyses in this population after 2011; however, our study had a longer follow-up time frame, had a larger patient sample size and focused on treatment distribution across multiple lines of therapy, rather than focusing on first line or survival. One prior study was an analysis of EMRs from the Flatiron database (Flatiron Health, NY, USA) that characterized treatment patterns and outcomes in patients with advanced melanoma, primarily in the first-line setting \[[@B17]\], and the other was a study of treatment patterns in the USA focusing on BRAF inhibitor treatment and survival outcomes specifically \[[@B18]\]. A third study focusing on US treatment patterns in relation to *BRAF* mutation testing from 2014 to 2016 was also performed; however, this analysis used patient claims data \[[@B19]\]. Two studies have assessed EMR data outside of the USA; one study focused on ipilimumab treatment patterns and outcomes in Europe and Australia \[[@B20]\], and the second study described broader treatment patterns and survival outcomes in France \[[@B21]\]. An observational study conducted via an online survey between August and November 2012 in Europe indicated that the most common first-line therapies for patients with *BRAF^Mut^* melanoma were vemurafenib (approved in Europe in February 2012 \[[@B22]\]) and dacarbazine; no single treatment was preferred for the second-line setting, potentially because of lack of access to and/or reimbursement for additional treatment modalities \[[@B23]\].

Real-world data provide important information about how the recently approved novel agents and combination therapies are actually being used by oncologists in clinical practice with the full range of patients, including those who would have been excluded from clinical trials, and can support more informed decisions about patient care \[[@B24],[@B25]\]. This study used the Oncology Services Comprehensive Electronic Records (OSCER) database (owned by Amgen Inc., CA, USA; periodic updates provided by Flatiron Health), a large repository of more than one million patients with cancer in the USA and was designed to describe the changing landscape of melanoma treatment over the 2011--2017 period. The study was intended to analyze treatment trends as new medications became available and to include the demographic and clinical characteristics of patients with advanced melanoma (predominantly stages III--IV) by *BRAF* mutation status. This analysis used patient-level data that contain information on biomarker status (*BRAF*), a level of detail not often employed in previous studies for mutations known to be associated with adverse outcomes.

The primary objectives of this study were to describe demographic and clinical characteristics of patients with advanced melanoma and to describe pharmacologic treatment patterns, by line of therapy, by year and by stage, using the OSCER structured dataset. Other objectives were to describe these same characteristics according to *BRAF* mutation status using the OSCER enhanced dataset.

Patients & methods {#S0001}
==================

Study design {#S0002}
------------

We conducted a retrospective cohort study to describe treatment patterns in patients with advanced melanoma over a 6-year period beginning in 2011 (see Supplementary Data, [Supplementary Figure 1](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). Baseline patient characteristics were collected from the 12-month period before the date of the first melanoma diagnosis (i.e., index date). Patient data were then collected from index date through death or end of study (Structured OSCER, 30 August 2017; enhanced dataset, 31 December 2016).

Data source {#S0003}
-----------

The OSCER collection is a proprietary database of EMRs held by cancer care providers across the USA that provides real-world clinical data representing approximately 20% of all US patients with cancer. This cloud-based oncology record system is used by more than 500 community oncology treatment centers and covers roughly 240 clinics, 2000 clinicians and 1,100,000 cancer patients. Two datasets were included in this analysis. The structured dataset included structured data obtained from patient-level EMRs from OSCER for patients who had received systemic therapy. The enhanced dataset included data abstracted from unstructured data obtained from physicians' notes and laboratory reports in addition to structured elements and included all patients, regardless of treatment received. The enhanced dataset also included biomarker testing results (i.e., *BRAF*).

Patient selection {#S0004}
-----------------

The structured dataset included patients aged \>18 years identified in the OSCER database who were diagnosed with advanced melanoma (*International Classification of Diseases, Ninth Revision, Clinical Modification* \[ICD-9-CM\]: 172.xx/ICD-10: C43.xx, D03.xx) between 1 January 2011 and 31 July 2017, and initiated antimelanoma therapy within 90 days of diagnosis. Patients included in the enhanced dataset are patients with advanced melanoma derived from the structured dataset and diagnosed between 1 January 2011 and 30 November 2016. For all patients, there was a 1-month minimum of follow-up to capture data. All patients had a record of at least one antimelanoma administration of chemotherapy, immunotherapy or targeted therapy. To minimize the inclusion of patients who may have received treatment outside of the EMR system, all analyses that involved lines of therapy only included patients who began treatment within 90 days of the diagnosis index date. Patients with any record of other primary malignant tumors in the year before melanoma diagnosis, with ICD codes V10.82 and Z85.820 (personal history of malignant melanoma of the skin) before the index date, aged \<19 years (to allow ≥1 year of baseline or preindex period), or with evidence of data discrepancies (e.g., diagnosis date before birth year, date of treatment initiation before diagnosis date) were excluded.

Outcomes {#S0005}
--------

Treatment patterns in patients with advanced melanoma receiving systemic therapy overall, by disease stage at diagnosis, by line of therapy and by year of melanoma diagnosis (index year) were analyzed in the OSCER structured and enhanced datasets. Treatment patterns by biomarker status were also analyzed for the OSCER enhanced dataset. Demographic and clinical characteristics of patients with melanoma receiving drug treatment overall, by disease stage, by year and by line of therapy for the OSCER structured datasets are reported, as are those by biomarker status for the OSCER enhanced dataset. Stage is based on the disease reported at diagnosis; patients in a real-world treatment setting are not commonly restaged after treatment is started.

Statistical analyses {#S0006}
--------------------

In addition to the yearly analyses, analyses over time compared the 2011--2014 and 2015--2017 periods and reported absolute differences in therapy use to capture major shifts in the treatment landscape of advanced melanoma. In the 2011--2014 period, the first immunotherapy and targeted therapy agents were approved, and in 2015--2017, newer agents, such as combinations of cobimetinib and vemurafenib were approved for melanoma treatment \[[@B3]\].

The frequency of melanoma treatment patterns (i.e., the order and treatment received) was counted overall, by disease stage, by line of therapy and by year. First, second and third lines of melanoma therapy were identified by disease stage, *BRAF* mutation status and by year. Treatments were described by disease stage, by line of therapy, by year of melanoma diagnosis and by biomarker (in enhanced dataset). The time trends of therapy were described by year of melanoma diagnosis during the study period (i.e., 2011--2017). Demographic and clinical characteristics were summarized by disease stage, line of therapy, year of index diagnosis and biomarker status (continuous variables were summarized as mean and standard deviation; categorical variables were summarized as counts and percentages). Flatiron Health did not participate in the analyses of these data.

Results {#S0007}
=======

Patients {#S0008}
--------

Overall, 2628 patients listed in the OSCER database with melanoma who received drug therapy from 2011 to 2017 and who initiated therapy for melanoma within 90 days of diagnosis were included in the structured dataset. The enhanced dataset comprised 1687 patients with known *BRAF* mutation status from 2011 to 2016, 1161 of whom were patients with stage III (41% \[688/1687\]) or IV (28% \[473/1687\]) melanoma ([Table 1](#T1){ref-type="table"}, enhanced dataset). Demographic and clinical characteristics are shown in [Table 1](#T1){ref-type="table"}. In general, most patients were aged ≥40 years (structured dataset, 94% \[2460/2628\]; enhanced dataset, 93% \[1564/1687\]) and had stage III or IV disease at the time of first diagnosis (structured dataset, 40% \[1040/2628\], missing, 58% \[1514/2628\]; enhanced dataset, 69% \[1161/1687\], missing, 11% \[185/1687\]); slightly more than half (structured dataset, 51% \[1338/2628\]; enhanced dataset, 36% \[614/1687\]) had received at least two lines of systemic therapy. A greater incidence of lymph node metastasis was observed in patients with *BRAF^Mut^* tumors (13% \[72/557\]) compared with patients with *BRAF^WT^* tumors (11% \[124/1130\]).

###### Patient demographics and baseline clinical characteristics.

  Characteristic                      Structured Dataset (2011--2017)[^†^](#T1TFN1){ref-type="table-fn"}   Enhanced dataset (2011--2016)[^†^](#T1TFN1){ref-type="table-fn"}                              
  ----------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------ ------------- ------------ ------------
  Male                                657 (62.5)                                                           1040 (66.0)                                                        1136 (67.3)   367 (65.9)   769 (68.1)
  **Age**                                                                                                                                                                                                
  18--39                              85 (8.1)                                                             83 (5.3)                                                           123 (7.3)     50 (9.0)     73 (6.5)
  40--64                              483 (46.0)                                                           597 (37.9)                                                         727 (43.1)    288 (51.7)   439 (38.9)
  ≥65                                 483 (46.0)                                                           897 (56.9)                                                         837 (49.6)    219 (39.3)   618 (54.7)
  Adjuvant                            NA                                                                   NA                                                                 473 (28.0)    121 (21.7)   352 (31.2)
  **Line of therapy**                                                                                                                                                                                    
  1                                   1051 (100.0)                                                         1577 (100.0)                                                       1324 (78.5)   495 (88.9)   829 (73.4)
  2                                   369 (35.1)                                                           512 (32.5)                                                         435 (25.8)    203 (36.5)   232 (20.5)
  3                                   158 (15.0)                                                           166 (10.5)                                                         128 (7.6)     73 (13.1)    55 (4.9)
  4+                                  84 (8.0)                                                             49 (3.1)                                                           51 (3.0)      26 (4.7)     25 (2.2)
  **ECOG score**                                                                                                                                                                                         
  0                                   268 (25.5)                                                           510 (32.3)                                                         585 (34.7)    198 (35.6)   387 (34.3)
  1                                   130 (12.4)                                                           369 (23.4)                                                         265 (15.7)    78 (14.0)    187 (16.6)
  2                                   38 (3.6)                                                             126 (8.0)                                                          85 (5.0)      25 (4.5)     60 (5.3)
  3                                   16 (1.5)                                                             39 (2.5)                                                           24 (1.4)      10 (1.8)     14 (1.2)
  4                                   1 (0.1)                                                              4 (0.3)                                                            7 (0.4)       3 (0.5)      4 (0.4)
  Missing                             598 (56.9)                                                           529 (33.5)                                                         721 (42.7)    243 (43.6)   478 (42.3)
  **Disease stage**                                                                                                                                                                                      
  I                                   4 (0.4)                                                              6 (0.4)                                                            90 (5.3)      37 (6.6)     53 (4.7)
  II                                  30 (2.9)                                                             34 (2.2)                                                           251 (14.9)    76 (13.6)    175 (15.5)
  III                                 93 (8.9)                                                             147 (9.3)                                                          688 (40.8)    191 (34.3)   497 (44.0)
  IV                                  256 (24.4)                                                           544 (34.5)                                                         473 (28.0)    195 (35.0)   278 (24.6)
  Missing                             668 (63.6)                                                           846 (53.7)                                                         185 (11.0)    58 (10.4)    127 (11.2)
  **Site of metastasis**                                                                                                                                                                                 
  Lung                                11 (1.1)                                                             120 (7.6)                                                          253 (15.0)    89 (16.0)    164 (14.5)
  Bone                                9 (0.9)                                                              127 (8.1)                                                          74 (4.4)      37 (6.6)     37 (3.3)
  Brain                               8 (0.8)                                                              117 (7.4)                                                          94 (5.6)      54 (9.7)     40 (3.5)
  Liver                               4 (0.4)                                                              70 (4.4)                                                           48 (2.9)      19 (3.4)     29 (2.6)
  Skin                                2 (0.2)                                                              16 (1.0)                                                           20 (1.2)      12 (2.2)     8 (0.7)
  Lymph nodes                         2 (0.2)                                                              83 (5.3)                                                           196 (11.6)    72 (12.9)    124 (11.0)
  Other                               25 (2.4)                                                             123 (7.8)                                                          325 (19.3)    134 (24.1)   191 (16.9)
  **Number of sites of metastases**                                                                                                                                                                      
  1                                   18 (1.7)                                                             235 (14.9)                                                         422 (25.0)    158 (28.4)   264 (23.4)
  2                                   6 (0.6)                                                              76 (4.8)                                                           179 (10.6)    81 (14.5)    98 (8.7)
  3+                                  20 (1.9)                                                             99 (6.3)                                                           71 (4.2)      29 (5.2)     42 (3.7)
  NA                                  1007 (95.8)                                                          1167 (74.0)                                                        1015 (60.2)   289 (51.9)   726 (64.3)

Data are presented as n (%).

Structured dataset included patients who had received systemic therapy; enhanced dataset included all patients, regardless of treatment received.

ECOG: Eastern Cooperative Oncology Group; NA: Not available; OSCER: Oncology Services Comprehensive Electronic Records.

Treatment patterns {#S0009}
------------------

Therapies for advanced melanoma included checkpoint inhibitors (66% \[1722/2628\]), BRAF/MEK inhibitors (21% \[561/2628\]), cytokines (19% \[504/2628\]), and chemotherapy (13% \[339/2628\]).

### Treatment patterns over the period evaluated (structured dataset) {#S0010}

Overall, the use of checkpoint inhibitor treatments increased from 21% (38/182) in 2011 to 84% (845/1008) in 2017 ([Figure 1](#F1){ref-type="fig"}A). Ipilimumab remained the sole US FDA--approved checkpoint inhibitor until 2014, at which point its use as a monotherapy decreased with the increased use of other monotherapy inhibitors and combination therapy of ipilimumab plus nivolumab ([Table 2](#T2){ref-type="table"}). The overall use of BRAF and MEK inhibitors remained fairly stable from 2013 to 2017 (approximately 20%); however, by 2017, the use of vemurafenib monotherapy (2% \[22/1008\]) was largely replaced by the BRAF/MEK inhibitor combinations, mainly dabrafenib + trametinib and less frequently, cobimetinib + vemurafenib (15% \[153/1008\] and 5% \[45/1008\]; [Table 2](#T2){ref-type="table"}). Additionally, cytokine and chemotherapy use declined over the period evaluated (45% \[82/182\] to 4% \[38/1008\] and 36% \[65/182\] to 4% \[42/1008\], respectively); however, the use of high-dose interleukin-2 (IL-2) (i.e., aldesleukin) remained low and constant over the course of the study (\<1%).

![Treatment patterns.\
By **(A)** year and line of treatment for **(B)** checkpoint inhibitors, **(C)** BRAF/MEK inhibitors, **(D)** cytokines and **(E)** chemotherapy in the Structured Dataset.](mmt-06-31-g1){#F1}

###### Melanoma treatment by year for all patients (structured dataset).

  Drug agent                                                  Overall (N = 2628)   2011 (n = 182)   2012 (n = 348)   2013 (n = 365)   2014 (n = 473)   2015 (n = 609)   2016 (n = 1083)   2017 (n = 1008)
  ----------------------------------------------------------- -------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------- -----------------
  Checkpoint inhibitors[^†^](#T2TFN1){ref-type="table-fn"}    1722 (65.5)          38 (20.9)        101 (29.0)       130 (35.6)       216 (45.7)       365 (59.9)       840 (77.6)        845 (83.8)
  -- Ipilimumab                                               729 (27.7)           38 (20.9)        101 (29.0)       130 (35.6)       204 (43.1)       154 (25.3)       176 (16.3)        138 (13.7)
  -- Pembrolizumab                                            496 (18.9)           --               --               --               34 (7.2)         130 (21.3)       262 (24.2)        308 (30.6)
  -- Nivolumab                                                410 (15.6)           --               --               --               --               91 (14.9)        248 (22.9)        247 (24.
  -- Ipilimumab + nivolumab                                   388 (14.8)           --               --               --               --               48 (7.9)         240 (22.2)        234 (23.2)
  BRAF/MEK inhibitors[^‡^](#T2TFN2){ref-type="table-fn"}      561 (21.3)           10 (5.5)         62 (17.8)        83 (22.7)        107 (22.6)       115 (18.9)       232 (21.4)        219 (21.7)
  -- Dabrafenib                                               51 (1.9)             --               --               7 (1.9)          13 (2.7)         4 (0.7)          21 (1.9)          18 (1.8)
  -- Trametinib                                               37 (1.4)             --               --               3 (0.8)          10 (2.1)         6 (1.0)          12 (1.1)          13 (1.3)
  -- Vemurafenib                                              192 (7.3)            10 (5.5)         62 (17.8)        75 (20.5)        47 (9.9)         32 (5.3)         33 (3.0)          22 (2.2)
  -- Cobimetinib                                              6 (0.2)              --               --               --               --               --               3 (0.3)           4 (0.4)
  -- Dabrafenib + trametinib                                  324 (12.3)           --               --               4 (1.1)          55 (11.6)        79 (13.0)        161 (14.9)        153 (15.2)
  -- Cobimetinib + vemurafenib                                67 (2.5)             --               --               --               --               4 (0.7)          39 (3.6)          45 (4.5)
  Other targeted therapy[^§^](#T2TFN3){ref-type="table-fn"}   30 (1.1)             --               6 (1.7)          5 (1.4)          10 (2.1)         11 (1.8)         15 (1.4)          14 (1.4)
  Cytokines                                                   504 (19.2)           82 (45.1)        147 (42.2)       130 (35.6)       143 (30.2)       130 (21.3)       79 (7.3)          38 (3.8)
  -- Interferon α-2β                                          502 (19.1)           82 (45.1)        147 (42.2)       129 (35.3)       142 (30.0)       130 (21.3)       78 (7.2)          38 (3.8)
  -- Peginterferon α-2β                                       142 (5.4)            19 (10.4)        40 (11.5)        44 (12.1)        45 (9.5)         42 (6.9)         26 (2.4)          10 (1.0)
  -- Aldesleukin                                              4 (0.2)              --               --               1 (0.3)          1 (0.2)          1 (0.2)          1 (0.1)           --
  Chemotherapy                                                339 (12.9)           65 (35.7)        73 (21.0)        71 (19.5)        68 (14.4)        57 (9.4)         46 (4.2)          42 (4.2)
  -- Temozolomide                                             147 (5.6)            40 (22.0)        41 (11.8)        35 (9.6)         26 (5.5)         12 (2.0)         9 (0.8)           14 (1.4)
  -- Fluorouracil                                             73 (2.8)             4 (2.2)          7 (2.0)          9 (2.5)          20 (4.2)         23 (3.8)         13 (1.2)          10 (1.0)
  -- Carboplatin                                              73 (2.8)             9 (4.9)          15 (4.3)         16 (4.4)         12 (2.5)         10 (1.6)         17 (1.6)          14 (1.4)
  -- Paclitaxel[^¶^](#T2TFN4){ref-type="table-fn"}            95 (3.6)             11 (6.0)         18 (5.2)         21 (5.8)         20 (4.2)         16 (2.6)         19 (1.8)          18 (1.8)
  -- Dacarbazine                                              49 (1.9)             12 (6.6)         10 (2.9)         10 (2.7)         7 (1.5)          6 (1.0)          3 (0.3)           6 (0.6)
  -- Cisplatin                                                25 (1.0)             2 (1.1)          11 (3.2)         2 (0.5)          2 (0.4)          4 (0.7)          3 (0.3)           5 (0.5)
  -- Cyclophosphamide                                         2 (0.1)              --               --               1 (0.3)          2 (0.4)          1 (0.2)          1 (0.1)           1 (0.1)
  -- Other chemotherapy                                       1 (0.04)             --               --               --               --               --               1 (0.1)           --

Data are presented as n (%).

FDA approval dates of checkpoint inhibitors for melanoma treatment: ipilimumab, March 2011; pembrolizumab, September 2014; nivolumab, December 2014.

FDA approval dates of BRAF/MEK inhibitors for melanoma treatment: dabrafenib, May 2013; trametinib, May 2013; vemurafenib, August 2011; cobimetinib, November 2015.

Other targeted therapies included bevacizumab, bortezomib, rituximab, and ruxolitinib phosphate.

And Paclitaxel protein bound.

FDA: US Food and Drug Administration.

For patients with stage III disease (n = 240), use of checkpoint inhibitors increased from 13% (3/24) to 87% (93/107) from 2011 to 2017, corresponding with a decreased use of cytokines from 96% (23/24) in 2011 to 11% (12/107) in 2017 (see Supplementary Data, [Supplementary Table 1](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). Use of BRAF/MEK inhibitors was initially limited (3% \[1/34\] in 2012) but increased over the period evaluated (18% \[19/107\] in 2017). Use of chemotherapy was minimal (3% \[7/240\] overall).

For patients with stage IV disease (n = 800), use of checkpoint inhibitors also increased from 2011 to 2017, from 35% (15/43) to 90% (333/372; see Supplementary Data, [Supplementary Table 2](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). Additionally, the use of BRAF/MEK inhibitors increased from 9% (4/43) in 2011 to 24% (88/372) in 2017. Cytokine use decreased from 9% (4/43) in 2011 to 1% (1/372) in 2015 and 0% in 2016 and 2017. Chemotherapy use also decreased from 53% (23/43) in 2011 to 3% (13/372) in 2017.

### Treatment patterns by line of therapy (structured dataset) {#S0011}

Checkpoint inhibitors were the most commonly administered treatment for the first line of therapy (57% \[1498/2628\]; see Supplementary Data, [Supplementary Table 3](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)) and across later lines of therapy (ranging from 59% \[190/324\] to 66% \[88/133\]). Of note, the use of pembrolizumab (13% \[349/2628\] in first line to 28% \[37/133\] in fourth line) and ipilimumab/nivolumab (10% \[255/2628\] in first line to 16% \[21/133\] in fourth line) increased in later lines of therapy ([Figure 1](#F1){ref-type="fig"}B). The next most commonly used treatments overall were BRAF/MEK inhibitors (21% \[561/2628\]; [Figure 1](#F1){ref-type="fig"}C) and cytokines (19% \[504/2628\]; [Figure 1](#F1){ref-type="fig"}D), respectively, followed by chemotherapy (13% \[339/2628\]; [Figure 1](#F1){ref-type="fig"}E). When BRAF/MEK inhibitors were used, vemurafenib use was higher in first-line therapy (39% \[149/381\] of BRAF/MEK inhibitor treatments) compared with fourth-line therapy (28% \[18/64\]), whereas the use of other BRAF and MEK inhibitors increased in later lines of therapy. Cytokine use was predominantly observed as first (19% \[499/2628\]) and second lines (10% \[84/881\]) of therapy compared with later lines (5--6%) of therapy.

For patients with stage III disease (n = 367), checkpoint inhibitor use increased with later lines of therapy (first line, 53% \[128/240\]; fourth line, 86% \[12/14\]; [Table 3](#T3){ref-type="table"}). Use of BRAF/MEK inhibitors also increased with later lines of therapy (first line, 4% \[10/240\]; fourth line, 43% \[6/14\]). Conversely, cytokine use decreased from 42% (101/240) in the first-line setting to 0% in the fourth-line setting, suggesting an absolute decrease in their use over time.

###### Melanoma treatment by line of therapy for patients by disease stage (structured dataset).

  Drug agent                                                  Stage III (n = 367)   Stage IV (n = 1172)                                                                 
  ----------------------------------------------------------- --------------------- --------------------- ----------- ----------- ------------ ------------ ----------- -----------
  Checkpoint inhibitors[^†^](#T3TFN1){ref-type="table-fn"}    128 (53.3)            58 (69.9)             21 (70.0)   12 (85.7)   590 (73.8)   183 (70.1)   45 (52.9)   16 (61.5)
  -- Ipilimumab                                               105 (43.8)            34 (41.0)             13 (43.3)   8 (57.1)    176 (22.0)   53 (20.31)   18 (21.2)   3 (11.5)
  -- Pembrolizumab                                            11 (4.6)              13 (15.7)             4 (13.3)    2 (14.3)    143 (17.9)   48 (18.4)    13 (15.3)   9 (34.6)
  -- Nivolumab                                                6 (2.5)               7 (8.4)               1 (3.3)     2 (14.3)    133 (16.6)   45 (17.2)    8 (9.4)     5 (19.2)
  -- Ipilimumab + nivolumab                                   6 (2.5)               4 (4.8)               3 (10.0)    2 (14.3)    138 (17.3)   51 (19.5)    10 (11.8)   2 (7.7)
  BRAF/MEK inhibitors[^‡^](#T3TFN2){ref-type="table-fn"}      10 (4.2)              12 (14.5)             10 (33.3)   6 (42.9)    143 (17.9)   104 (39.9)   41 (48.2)   12 (46.2)
  -- Dabrafenib                                               --                    1 (1.2)               1 (3.3)     --          8 (1.0)      5 (1.9)      5 (5.9)     4 (15.4)
  -- Trametinib                                               --                    --                    --          2 (14.3)    2 (0.3)      10 (3.8)     1 (1.2)     2 (7.7)
  -- Vemurafenib                                              4 (1.7)               3 (3.6)               1 (3.3)     --          51 (6.4)     22 (8.4)     5 (5.9)     1 (3.9)
  -- Cobimetinib                                              --                    --                    --          --          --           2 (0.8)      1 (1.2)     --
  -- Dabrafenib + trametinib                                  3 (1.3)               5 (6.0)               8 (26.7)    5 (35.7)    71 (8.9)     56 (21.5)    27 (31.8)   6 (23.1)
  -- Cobimetinib + vemurafenib                                3 (1.3)               3 (3.6)               --          1 (7.1)     13 (1.6)     14 (5.4)     5 (5.9)     4 (15.4)
  Other targeted therapy[^§^](#T3TFN3){ref-type="table-fn"}   --                    --                    --          --          2 (0.3)      2 (0.8)      --          --
  Cytokines                                                   101 (42.1)            17 (20.5)             2 (6.7)     --          10 (1.3)     3 (1.2)      1 (1.2)     --
  -- Interferon α-2β                                          101 (42.1)            17 (20.5)             2 (6.7)     --          10 (1.3)     3 (1.2)      1 (1.2)     --
  -- Peginterferon α-2β                                       26 (10.8)             11 (13.3)             1 (3.3)     --          2 (0.3)      1 (0.4)      --          --
  -- Aldesleukin                                              --                    --                    --          --          --           --           --          --
  Chemotherapy                                                1 (0.4)               4 (4.8)               1 (3.3)     2 (14.3)    59 (7.4)     41 (15.7)    20 (23.5)   6 (23.1)
  -- Temozolomide                                             --                    2 (2.4)               1 (3.3)     1 (7.1)     33 (4.1)     15 (5.8)     10 (11.8)   5 (19.2)
  -- Fluorouracil                                             1 (0.4)               --                    --          --          --           --           --          --
  -- Carboplatin                                              --                    --                    --          --          10 (1.3)     19 (7.3)     4 (4.7)     --
  -- Paclitaxel[^¶^](#T3TFN4){ref-type="table-fn"}            --                    --                    --          --          12 (1.5)     19 (7.3)     8 (9.4)     2 (7.7)
  -- Dacarbazine                                              --                    2 (2.4)               --          2 (14.3)    10 (1.3)     6 (2.3)      4 (4.7)     1 (3.9)
  -- Cisplatin                                                --                    --                    --          1 (7.1)     5 (0.6)      4 (1.5)      1 (1.2)     1 (3.9)
  -- Cyclophosphamide                                         --                    --                    --          --          --           --           --          --
  -- Other chemotherapy                                       --                    --                    --          --          --           --           --          --

Data are presented as n (%).

Therapies were not exclusive; patients may have received multiple therapies.

FDA approval dates of checkpoint inhibitors for melanoma treatment: ipilimumab, March 2011; pembrolizumab, September 2014; nivolumab, December 2014.

FDA approval dates of BRAF/MEK inhibitors for melanoma treatment: dabrafenib, May 2013; trametinib, May 2013; vemurafenib, August 2011; cobimetinib, November 2015.

Other targeted therapies included bevacizumab, bortezomib, rituximab, and ruxolitinib phosphate.

And Paclitaxel protein bound.

FDA: US Food and Drug Administration; 1L: First line; 2L: Second line; 3L: Third line; 4L: Fourth line.

In contrast to patients with stage III disease, use of checkpoint inhibitors decreased across later lines of therapy for patients with stage IV disease (n = 1172), and cytokine therapy use remained low throughout all lines of therapy ([Table 3](#T3){ref-type="table"}). BRAF/MEK inhibitor use and chemotherapy were more prevalent in patients with stage IV disease; for both, use increased across later lines of therapy.

### Treatment patterns by biomarker status (enhanced dataset) {#S0012}

For patients with *BRAF^Mut^* tumors, checkpoint inhibitor use was higher overall (see Supplementary Data, [Supplementary Figure 2](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)) and higher in patients with stage III disease (62% \[119/191\]) than in those with stage IV disease (52% \[102/195\]). In contrast, for patients with *BRAF^Wt^* tumors, checkpoint inhibitor use overall was lower in patients with stage III disease (52% \[258/497\]) than in those with stage IV disease (90% \[250/278\]; [Figure 2](#F2){ref-type="fig"}A; [Table 4](#T4){ref-type="table"}). BRAF/MEK inhibitors were the most commonly used agents for both stage III and IV *BRAF^Mut^* disease overall (65% \[249/386\]). Furthermore, BRAF/MEK inhibitors were used in a higher percentage of patients with *BRAF^Mut^* stage IV disease (79% \[154/195\]) than those with *BRAF^Mut^* stage III disease (50% \[95/191\]; [Figure 2](#F2){ref-type="fig"}B). Cytokines were more commonly used for patients with both *BRAF^Mut^* and *BRAF^Wt^* stage III disease (37% \[70/191\]; 46% \[228/497\]) versus stage IV disease (1% \[2/195\]; 4% \[10/278\]; [Figure 2](#F2){ref-type="fig"}C). Chemotherapy use was similar for patients with *BRAF^Mut^* stage III (5% \[10/191\]) or stage IV (6% \[11/195\]) disease; use was slightly higher in patients with *BRAF^Wt^* stage IV disease (18% \[51/278\]) versus stage III disease (8% \[39/497\]; [Figure 2](#F2){ref-type="fig"}D).

![Treatment patterns.\
For **(A)** checkpoint inhibitors, **(B)** BRAF/MEK inhibitors, **(C)** cytokines and **(D)** chemotherapy by disease stage and *BRAF* status in the enhanced dataset.](mmt-06-31-g2){#F2}

###### Melanoma treatment for patients by biomarker status and disease stage (enhanced dataset).

  Drug agent                                                  Overall (N = 1161)   *BRAF^Mut^*   *BRAF^Wt^*                                          
  ----------------------------------------------------------- -------------------- ------------- ------------ ------------ ------------ ------------ ------------
  Checkpoint inhibitors[^†^](#T4TFN1){ref-type="table-fn"}    729 (62.8)           221 (57.3)    119 (62.3)   102 (52.3)   508 (65.5)   258 (51.9)   250 (89.9)
  -- Ipilimumab                                               441 (38)             110 (28.5)    59 (30.9)    51 (26.2)    331 (42.7)   173 (34.8)   158 (56.8)
  -- Pembrolizumab                                            168 (14.5)           52 (13.5)     29 (15.2)    23 (11.8)    116 (15)     61 (12.3)    55 (19.8)
  -- Nivolumab                                                162 (14.0)           59 (15.3)     35 (18.3)    24 (12.3)    103 (13.3)   50 (10.1)    53 (19.1)
  -- Ipilimumab + nivolumab                                   115 (9.9)            42 (10.9)     20 (10.5)    22 (11.3)    73 (9.4)     34 (6.8)     39 (14.0)
  BRAF/MEK inhibitors[^‡^](#T4TFN2){ref-type="table-fn"}      262 (22.6)           249 (64.5)    95 (49.7)    154 (79.0)   13 (1.7)     10 (2.0)     3 (1.1)
  -- Dabrafenib                                               31 (2.7)             30 (7.8)      12 (6.3)     18 (9.2)     1 (0.1)      1 (0.2)      --
  -- Trametinib                                               17 (1.5)             15 (3.9)      6 (3.1)      9 (4.6)      2 (0.3)      2 (0.4)      --
  -- Vemurafenib                                              98 (8.4)             94 (24.4)     34 (17.8)    60 (30.8)    4 (0.5)      2 (0.4)      2 (0.7)
  -- Cobimetinib                                              2 (0.2)              2 (0.5)       --           2 (1.0)      --           --           --
  -- Dabrafenib + trametinib                                  158 (13.6)           153 (39.6)    58 (30.4)    95 (48.7)    5 (0.6)      4 (0.8)      1 (0.4)
  -- Cobimetinib + vemurafenib                                13 (1.1)             12 (3.1)      5 (2.6)      7 (3.6)      1 (0.1)      1 (0.2)      --
  Other targeted therapy[^§^](#T4TFN3){ref-type="table-fn"}   15 (1.3)             8 (2.1)       4 (2.1)      4 (2.1)      7 (0.9)      3 (0.6)      4 (1.4)
  Cytokines                                                   310 (26.7)           72 (18.7)     70 (36.6)    2 (1.0)      238 (30.7)   228 (45.9)   10 (3.6)
  -- Interferon α-2β                                          309 (26.6)           72 (18.7)     70 (36.6)    2 (1.0)      237 (30.6)   227 (45.7)   10 (3.6)
  -- Peginterferon α-2β                                       89 (7.7)             19 (4.9)      18 (9.4)     1 (0.5)      70 (9.0)     68 (13.7)    2 (0.7)
  -- Aldesleukin                                              4 (0.3)              2 (0.5)       2 (1.0)      --           2 (0.3)      1 (0.2)      1 (0.4)
  Chemotherapy                                                111 (9.6)            21 (5.4)      10 (5.2)     11 (5.6)     90 (11.6)    39 (7.8)     51 (18.3)
  -- Temozolomide                                             56 (4.8)             8 (2.1)       5 (2.6)      3 (1.5)      48 (6.2)     19 (3.8)     29 (10.4)
  -- Fluorouracil                                             6 (0.5)              1 (0.3)       --           1 (0.5)      5 (0.6)      5 (1.0)      --
  -- Carboplatin                                              44 (3.8)             8 (2.1)       5 (2.6)      3 (1.5)      36 (4.6)     18 (3.6)     18 (6.5)
  -- Paclitaxel[^¶^](#T4TFN4){ref-type="table-fn"}            46 (4)               9 (2.3)       3 (1.6)      6 (3.1)      37 (4.8)     15 (3.0)     22 (7.9)
  -- Dacarbazine                                              13 (1.1)             2 (0.5)       --           2 (1.0)      11 (1.4)     2 (0.4)      9 (3.2)
  -- Cisplatin                                                7 (0.6)              --            --           --           7 (0.9)      5 (1.0)      2 (0.7)
  -- Cyclophosphamide                                         --                   --            --           --           --           --           --
  -- Other chemotherapy                                       4 (0.3)              1 (0.2)       --           1 (0.5)      3 (0.4)      3 (0.6)      --

Data are presented as n (%).

FDA approval dates of checkpoint inhibitors for melanoma treatment: ipilimumab, March 2011; pembrolizumab, September 2014; nivolumab, December 2014.

FDA approval dates of BRAF/MEK inhibitors for melanoma treatment: dabrafenib, May 2013; trametinib, May 2013; vemurafenib, August 2011; cobimetinib, November 2015.

Other targeted therapies included bevacizumab, bortezomib, rituximab, and ruxolitinib phosphate.

And paclitaxel protein-bound.

FDA: US Food and Drug Administration.

Stratified data from 2011 to 2013 for patients with either *BRAF^Mut^* or *BRAF^Wt^* stage III or IV disease are limited (see Supplementary Data, [Supplementary Tables 4--7](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). From 2014 to 2016, BRAF/MEK inhibitors and checkpoint inhibitors were the most commonly used therapies across all lines of therapy for patients with *BRAF^Mut^* stage III or IV disease (see Supplementary Data, [Supplementary Tables 8 & 9](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). For patients with *BRAF^Wt^* stage III or IV disease, checkpoint inhibitors and chemotherapy were the most commonly used treatments from 2014 to 2016 across all lines of therapy (see Supplementary Data, [Supplementary Tables 10 & 11](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). Although uncommon, use of BRAF/MEK inhibitors was observed in patients with *BRAF^Wt^* tumors, mostly in patients with stage III disease (see Supplementary Data, [Supplementary Tables 10 & 11](/doi/suppl/10.2217/mmt-2019-0013/suppl_file/mmt-06-31-s1.pdf)). Use of cytokines and targeted therapies other than BRAF and MEK inhibitors was sporadic, regardless of *BRAF* mutation status, disease stage or time period.

Discussion {#S0013}
==========

Data from real-world analyses such as the ones reported here could further augment clinician knowledge and help guide treatment selections. In this analysis, checkpoint inhibitors were the most commonly prescribed drug therapy overall for patients with advanced melanoma, regardless of *BRAF* mutation and stage. Additionally, checkpoint inhibitors, BRAF/MEK inhibitors and chemotherapy were the predominant choices for later-line therapies after first-line treatment for stage IV disease. Other targeted therapies and cytokines, including high-dose IL-2, were less prescribed.

Most melanoma patients with *BRAF^Mut^* tumors (65%) were initially prescribed BRAF/MEK inhibitors. Notably, the use of later FDA-approved BRAF (i.e., dabrafenib) and MEK (trametinib and cobimetinib) inhibition for the treatment of advanced melanoma increased compared with the use of the first BRAF inhibitor monotherapy (vemurafenib) approved in 2011. In patients with *BRAF* mutations, BRAF/MEK inhibitors were more commonly prescribed for treatment in stage IV than in stage III melanoma. This could reflect changes in the treatment landscape because BRAF/MEK inhibitors may not have been approved for use when the patients included in this report were diagnosed and received first-line treatment. The use of other targeted therapies (i.e., rituximab, bevacizumab, bortezomib and ruxolitinib phosphate) was sparse and occurred mostly as single-agent use in the first- and second-line settings for patients with stage IV melanoma or those who did not meet the criteria for receiving one of the other therapeutic options. Although it has also been suggested that targeted therapy with BRAF/MEK inhibitors may be used for patients with *BRAF^Mut^* tumors who have a higher comorbidity burden, including brain metastases \[[@B19]\], recent analyses suggest that checkpoint inhibitors may be the preferred first-line option for patients with brain metastases, given that they appear to result in comparable overall response rates but higher rates of durable intracranial responses \[[@B26]\]. In stage III melanoma, checkpoint inhibitors were used more commonly in *BRAF^Mut^* compared with *BRAF^Wt^* melanomas, although the reasons for this could not be determined by this analysis. By contrast, in stage IV melanomas, the overall use of checkpoint inhibitors in any line of therapy was less in *BRAF^Mut^* compared with *BRAF^Wt^* melanomas. Chemotherapy was most widely used in patients with *BRAF^Wt^* stage IV melanoma compared with *BRAF^Wt^* stage III or *BRAF^Mut^* melanoma, presumably because of a lack of other viable options for such late-stage melanoma.

Results from this study indicate that treatment patterns for advanced melanoma changed from 2011 to 2017. Since their approval, checkpoint inhibitors and BRAF/MEK inhibitors are continuing to become more widely prescribed, whereas cytokines and chemotherapy are being used less. It is unsurprising that the use of interferon α-2β declined after 2014, given the approval of ipilimumab in 2015 as an adjuvant therapy for melanoma. Additionally, the increased uses of ipilimumab + nivolumab and nivolumab alone after 2015 were also foreseeable, given that the escalation corresponded with the publication of the initial results from the CheckMate 067 trial that demonstrated improved outcomes with nivolumab + ipilimumab or nivolumab alone versus ipilimumab alone in patients with metastatic melanoma \[[@B27]\]. These practices align with the current National Comprehensive Cancer Network \[[@B28]\] and European Society for Medical Oncology \[[@B29]\] clinical practice guidelines, which recommend the use of anti--PD-1 inhibitors (i.e., nivolumab and pembrolizumab) or nivolumab + ipilimumab as first-line therapy for all advanced melanoma patients, or combination therapy with BRAF/MEK inhibitors for patients with *BRAF^Mut^* melanoma \[[@B28],[@B29]\]. Recommended second-line options include the use of checkpoint inhibitors and BRAF/MEK-targeted therapies for those with *BRAF^Mut^* disease, in addition to the use of systemic cytotoxic agents and high-dose IL-2 \[[@B28],[@B29]\]. Of note, despite the recommendations to use BRAF/MEK inhibitors in combination as first-line treatment options (i.e., dabrafenib + trametinib, vemurafenib + cobimetinib, or encorafenib + binimetinib) \[[@B28],[@B29]\], some agents continue to be used as monotherapies. Additionally, although BRAF inhibitors are only recommended for patients with *BRAF^Mut^* melanoma \[[@B28],[@B29]\], their use as treatment for *BRAF^Wt^* disease was observed in a small percentage of patients. Additionally, the combination of dabrafenib + trametinib was prescribed more frequently than cobimetinib + vemurafenib. Interestingly, in the adjuvant setting, in addition to the preapproval use of nivolumab, pembrolizumab use among these patients was observed.

New agents continue to be approved for melanoma, and, as such, ongoing surveillance of treatment patterns will be necessary to capture the continually changing landscape of treatment options and practices. For example, the approved use of the intralesional oncolytic virus talimogene laherparepvec (IMLYGIC®; Amgen Inc., CA, USA) as monotherapy for previously resected melanoma no longer amenable to surgical therapy is listed in the National Comprehensive Cancer Network guidelines, and these same guidelines also recommend the use of talimogene laherparepvec in combination with ipilimumab for patients with metastatic or unresectable disease. Talimogene laherparepvec and other local therapies are not reported here, although they may be used in combination with the systemic therapies reported in this study.

A notable strength of the current study was the large, heterogeneous population of patients with melanoma identified through the OSCER database. This population included oncology practices across the USA, thus representing geographic diversity as well as multiple EMR systems, payer types and clinical pathways. Patient-level data were captured systematically and electronically from the same EMR used by practitioners to track patient care, resulting in improved consistency. Nevertheless, data limitations prevent complete ascertainment of treatment that occurs outside of the outpatient clinic setting, and analyses were limited by unknown or missing information in some EMR data fields captured by the OSCER database. For example, we lacked melanoma substage biopsy data, which could have otherwise provided greater insight into the reasons behind the choices of adjuvant therapies. Additionally, each EMR only captured patients' treatment at one clinic; it is possible that the patients could have received further treatment at another location that would not be captured by this study. Furthermore, the OSCER database does not include patients from every region of the USA. Therefore, analyses may be limited by regional differences in treatment, and results from this study may not be generalizable to a broader population of patients with melanoma in the USA.

A similar analysis of patient EMRs was recently published that evaluated treatment patterns identified from the Flatiron Health database in adult patients with advanced melanoma who initiated first-line therapy between 1 January 2014 and 30 June 2016; however, that analysis included fewer patients for a smaller follow-up window than was reported in this study and focused primarily on the first-line setting \[[@B17]\]. Results from that analysis were similar to those observed here; overall, most patients (\>50%) received a checkpoint inhibitor as either monotherapy or as combination therapy for first- or second-line therapy \[[@B17]\]. For patients with *BRAF^Mut^* disease, BRAF inhibitors were the most commonly prescribed treatment \[[@B17]\]. Fewer patients with *BRAF^Wt^* melanoma were noted to have received BRAF inhibitors in that study compared with this analysis \[[@B17]\].

The Flatiron Health database is a cloud-based database containing EMR data from \>265 cancer clinics in the USA. The prescribing patterns captured by EMR databases, such as the Flatiron Health database, may be geographically limited and not representative of those at different types of clinical practice, including at academic medical centers.

Similar treatment patterns were also observed in a recent analysis of two US claims databases that evaluated patients with *BRAF^Mut^* tumors with claims filed between 1 January 2014 and 30 June 2016 (Truven Health Analytics MarketScan, part of the IBM Watson Health™ business, MI, USA), or 30 September 2016 (IQVIA, NC, USA) \[[@B19]\].

Truven Health Analytics MarketScan and the IQVIA health services databases contain claims data from approximately 100 employers and \>100 US health plans, respectively. Similar to the geographic limitations noted for EMR databases, results from these two US claims databases are also limited in their generalizability to a broader population of patients with melanoma in the USA, given their regional focus.

Overall, the results from this analysis show that checkpoint inhibitors have largely replaced other therapies in the first-line setting for advanced melanoma, including for patients with *BRAF^Mut^* melanoma. Additionally, the uses of BRAF inhibitor monotherapies are being replaced by BRAF/MEK combination inhibitors. However, although this comprehensive study provides a more thorough understanding of the treatment choices for patients with advanced melanoma and the changes in the therapeutic landscape over the years, there are many questions that remain unanswered that could further inform clinical practice. For example, treatment patterns by disease substage and patient age are still unknown, as are the time intervals between various lines of treatment.

Data from these analyses describe the changing treatment patterns in the real world and, when considered alongside efficacy and safety data, provide useful information to help guide treatment selections with a goal to seeking optimal patient outcomes. Further analyses should enable clinicians to maintain a current understanding of the evolving treatment landscape in melanoma.

Conclusion {#S0014}
==========

In accordance with recent developments in the therapeutic landscape and with new treatment options available, checkpoint inhibitors have largely replaced other therapies in the first-line setting for treatment of advanced melanoma. For patients with *BRAF^Mut^* melanoma, major shifts also include BRAF inhibitors being replaced by BRAF/MEK combination inhibitors. Overall, advancements in the field since 2011 have provided more treatment options for advanced melanoma, regardless of *BRAF* mutation and stage.
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